NPR Health - Shots
DECEMBER 4, 2022
For decades birth control research focused on women. Now there's a new push to develop gels, pills or other products that could keep men from getting their partners pregnant.
pharmaphorum
DECEMBER 4, 2022
Clinical trials of a wireless brain chip developed by Elon Muck’s Neuralink company will be tested in human volunteers within the next six months – and Musk himself says he intends to have one implanted for a future demo event. Neuralink has been promising that the technology will be ready for clinical trials soon for some time – first saying they were around the corner back in 2019 – so the latest announcement by Musk at an update last week may be met with some scepticism.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
NPR Health - Shots
DECEMBER 4, 2022
Sangeeta Siwan lost her job and wasn't able to pay rent or feed her family. Her neighbors helped her survive. A study of giving in India during the pandemic shows she wasn't alone.
pharmaphorum
DECEMBER 4, 2022
Contrary to Big Tech, historically the pharmaceutical industry has had a good reputation for being a female-positive industry. However, both industries share a common problem: failure to provide women with C-suite opportunities. In fact, women hold only 11% of executive positions at Silicon Valley companies. The biopharma industry is worse, with women only accounting for 8% of CEO roles.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Medical Xpress
DECEMBER 4, 2022
China on Sunday reported two additional deaths from COVID-19 as some cities move cautiously to ease anti-pandemic restrictions amid increasingly vocal public frustration over the measures.
pharmaphorum
DECEMBER 4, 2022
Amgen is lagging behind rivals like Novo Nordisk and Eli Lilly with its new-generation therapy for obesity, but is sufficiently encouraged by early-stage clinical data to kick off a phase 2 programme for the drug next year. AMG 133 is a bispecific molecule that addresses two targets, GLP-1 and GIPR, and in a phase 1 study achieved clinically significant body weight reductions over 12 weeks in people with obesity and without diabetes, according to Amgen.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
pharmaphorum
DECEMBER 4, 2022
Amgen and Sanofi have said they may make cash-only offers for Horizon Therapeutics, which confirmed it was in talks with potential buyers last week, but Johnson & Johnson has ruled itself out of the running. Under Ireland’s financial regulations Amgen and Sanofi are required to acknowledge they are considering an offer – both stressing that none may arise – while J&J has to confirm it is not considering a bid for the business at the moment.
BioSpace
DECEMBER 4, 2022
Whether a job search is voluntary or not, the psychological toll of months of interviews, wrangling over pay and benefits and evaluating options has a weighty psychological toll.
Drug Patent Watch
DECEMBER 4, 2022
Annual Drug Patent Expirations for VIIBRYD Viibryd is a drug marketed by Allergan and is included in one NDA. It is available from four suppliers. There are four patents protecting…. The post New patent expiration for Allergan drug VIIBRYD appeared first on DrugPatentWatch - Make Better Decisions.
BioSpace
DECEMBER 4, 2022
FUJIFILM Diosynth Biotechnologies is offering unique opportunities to join one of the top global CDMOs focused on solving some of the most complex healthcare challenges.
Drug Patent Watch
DECEMBER 4, 2022
[
BioSpace
DECEMBER 4, 2022
???????SonoThera closed its Series A round of financing Monday, counting $60.75 million in earnings and will use these proceeds to advance its ultrasound-guided, non-viral gene therapy platform.
Drug Patent Watch
DECEMBER 4, 2022
[
BioSpace
DECEMBER 4, 2022
Monday, Verve Therapeutics revealed that the FDA has officially requested several buckets of additional safety information to lift the hold on its lead candidate, VERVE-101.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
NPR Health - Shots
DECEMBER 4, 2022
In New York City, Mayor Eric Adams plans to move homeless people with seeming mental illness to hospitals, possibly involuntarily.
BioSpace
DECEMBER 4, 2022
Janssen (Johnson & Johnson) is no longer in the running to acquire rare disease player Horizon Therapeutics, the company announced Saturday. This leaves Amgen and Sanofi at the bidding table.
Drug Patent Watch
DECEMBER 4, 2022
This chart shows the drugs with the most patents in Eurasian Patent Organization. Patents must be filed in each country (or, in some cases regional patent office) where patent protection…. The post Which pharmaceutical drugs have the most drug patents in Eurasian Patent Organization? appeared first on DrugPatentWatch - Make Better Decisions.
BioSpace
DECEMBER 4, 2022
Novartis announced the Phase III PSMAfore trial of Pluvicto for PSMA-positive metastatic castration-resistant prostate cancer met its primary endpoint.
JAMA Internal Medicine
DECEMBER 4, 2022
This systematic review and meta-analysis investigates whether female participants and racial and ethnic minority individuals are adequately represented in COVID-19 prevention and treatment trials in the US.
BioSpace
DECEMBER 4, 2022
TauRx Pharmaceuticals and Anavex Life Sciences presented positive results from their candidates at the Clinical Trials in Alzheimer’s Disease (CTAD) conference in San Francisco, CA.
Pharmaceutical Technology
DECEMBER 4, 2022
Starting in January, multiple biosimilars of AbbVie’s blockbuster drug Humira are set to flood the US pharmaceutical market. The arrival of Humira biosimilars is expected to provide cost-effective alternatives to the anti-tumor necrosis factor (TNF) biologic, but their eventual position on the market remains to be seen. Moreover, Humira’s behemoth status makes their introduction in the US particularly interesting.
Expert insights. Personalized for you.
141 
Let's personalize your content